A New Genetic Connection In Liver Cancer -- As Powerful As Her2/neu In Breast?
This article was originally published in Start Up
New data point to a targeted strategy for treating a significant subset of liver cancers and importantly, provide a biomarker for identifying patients who could benefit from the therapy. It's based on the discovery of a correlation between amplification of a growth factor gene and overexpression of the gene's protein product -- a phenomenon that mirrors the way in which amplified Her2/neu gene expression promotes a subset of breast cancer, which led to the development of Herceptin.
You may also be interested in...
Two independent research teams have shown that current RAF inchibitors, a class of experimental targeted cancer drugs, may only work well in patients with one particular mutation - in an enzyme called BRAF. In other people, the drugs can actually contribute to the growth of tumors. The findings echo develoments earlier in the decade with EGFr inhibitors, which proved to be harmful to some patients until the mechanism of action was worked out and their use subsequently restricted.
It's extraordinarily rare for a biomarker discovery to have a fast, clear-cut, and significant impact on a therapeutic area. But recent findings from a hepatitis C study--that a specific genetic variation strongly correlates with response to standard interferon-based therapy--could influence decision-making on when and how to treat certain HCV patients. What's more, the research may influence the design of clinical trials of new HCV agents and even trials in other diseases treated with interferon.
Traditional diagnostic tests for Her2 (the target of the drug Herceptin) have well-documented failings. In July, Monogram Biosciences launched a new Her2 test, and two months later, Genomic Health added Her2 status information to its breast cancer test. They believe that more comprehensive, multianalyte tests may better guide therapy and yield a pharmacoeconomic benefit, even at eight to 10 times the cost. These developments point to the need for a more nuanced approach to the management of cancer as a chronic disease and a more nuanced view of personalized medicine.